CompletedPhase 2NCT03594227
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
Studying Alopecia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aclaris Therapeutics, Inc.
- Principal Investigator
- Susan Moran, RNAclaris Therapeutics
- Intervention
- ATI-501 400mg BID (Low dose)(drug)
- Enrollment
- 87 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2019
Study locations (25)
- Aclaris Investigator Site, Hot Springs, Arkansas, United States
- Aclaris Investigator Site, Rogers, Arkansas, United States
- Aclaris Investigator Site, Denver, Colorado, United States
- Aclaris Investigator Site, Boynton Beach, Florida, United States
- Aclaris Investigator Site, Miami, Florida, United States
- Aclaris Investigator Site, Sanford, Florida, United States
- Aclaris Investigator Site, Snellville, Georgia, United States
- Aclaris Investigator Site, Clinton Township, Michigan, United States
- Aclaris Investigator Site, Detroit, Michigan, United States
- Aclaris Investigator Site, Fridley, Minnesota, United States
- Aclaris Investigator Site, Minneapolis, Minnesota, United States
- Aclaris Investigator Site, Saint Joseph, Missouri, United States
- Aclaris Investigator Site, Omaha, Nebraska, United States
- Aclaris Investigator Site, Las Vegas, Nevada, United States
- Aclaris Investigator Site, New York, New York, United States
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03594227 on ClinicalTrials.govOther trials for Alopecia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07487948Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen PlanopilarisIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT07533006A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)Eli Lilly and Company
- RECRUITINGPHASE3NCT07435012Androgenic Alopecia TH07 Clinical TrialTriple Hair Inc
- ENROLLING BY INVITATIONNCT07499713Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia AreataIstanbul Training and Research Hospital
- RECRUITINGNANCT07422376Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands RegionCharles Mays
- RECRUITINGNCT07226531Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the USPfizer
- RECRUITINGNANCT07563036JAK2 Expression in Androgenetic Alopecia Before and After Topical MinoxidilKasr El Aini Hospital
- RECRUITINGPHASE2NCT07370519Topical Application of Lactobacillus Reuteri for Androgenetic AlopeciaShenzhen People's Hospital